Pure Global AI
NCT06318507Recruiting

The Intestinal Microbiome in Triple Negative Breast Cancer Treated With Immunotherapy

Pennington Biomedical Research CenterClinicalTrials.govcombination product
Verified
Study focus
Disease/Condition
Breast Neoplasms
Drug/Device/Intervention
Fecal microbial diversity
Study type
Observational
Intervention type
combination product
Sponsor & location
Primary sponsor
Pennington Biomedical Research Center
Location
Baton Rouge, United States of America
Timeline & enrollment
Phase
N/A
Start date
Mar 11, 2024
End date
Dec 31, 2025
Enrollment
25 participants
Primary outcome

Pathologic Complete Response (pCR)

Summary

This study will determine how the intestinal microbiome differs between patients with obesity
 and early triple-negative breast cancer who achieve a pathologic complete response from
 preoperative anti-PD-1 immunotherapy (pembrolizumab) versus patients who do not.

ICD-10 classifications
Malignant neoplasm of breastMalignant neoplasm of breastMalignant neoplasm: Breast, unspecifiedBenign neoplasm of breastMalignant neoplasm: Central portion of breast
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06318507
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06318507 through Pure Global AI's free database. This phase not specified trial is sponsored by Pennington Biomedical Research Center and is currently Recruiting. The study focuses on Breast Neoplasms. Target enrollment is 25 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.